BPH Development, Progression Linked to Sleep Problems
Findings emerged from an analysis of data from 2588 men who participated in the REDUCE trial.
Findings emerged from an analysis of data from 2588 men who participated in the REDUCE trial.
In a study, 2-year survival rates were 14.4% for whites compared with 6.5% for blacks.
Likelihood of stone passage in patients on medical expulsive therapy is based on variables such as stone size and location and white blood cell count.
Finding could explain the association between obesity and diabetes and the development of kidney stones.
In a study, the 5-year risk of recurrence was 4.8%, 18.1%, and 46.3% for patients with low-, intermediate-, and high-risk disease.
Study finds no difference in metastasis-free survival observed after 15 years compared with radiation therapy or radical prostatectomy.
Nomograms specific to radical cystectomy currently do not exist to aid stratification of a patient’s risks for complications.
In a phase 2 trial, atezolizumab plus bevacizumab improved PFS versus sunitinib in patients with renal cell carcinoma expressing PD-L1.
Added progression-free survival and prolonged overall survival possible, according to investigators.
Researchers develop a model to predict which patients are more likely to harbor brain metastases at cancer diagnosis.